缩宫素(Oxytocin) - 药物靶点：OXTR_在研适应症：宫缩乏力，子宫出血，流产_专利_临床

概要

基本信息

简介催产素是一种以商品名OXYTOCIN®销售的OXTR激动剂，是一种因其在妇产科领域的临床疗效而受到称赞的药物。催产素由诺华公司制造，诺华是一家在药物创新方面享有盛誉的制药公司，它于1980年首次在美国获得批准。该药物主要用于产前和产后护理，因为它已被证明可以有效诱导或加强子宫收缩。它的重组激素性质使其成为全球妇产科医生的首选药物，他们为需要产前和产后护理的女性寻求可靠和值得信赖的选择。此外，已发现催产素是孕妇常用的处方药，可帮助她们分娩和分娩或控制产后出血。

药物类型

合成多肽

别名

Oxytocin (JP17/USP/INN)、Oxytocin Nasal Spray、催产素

+ [14]

靶点

OXTR

作用机制

OXTR激动剂(催产素受体激动剂)

治疗领域

泌尿生殖系统疾病其他疾病神经系统疾病+ [2]

在研适应症

宫缩乏力子宫出血流产+ [11]

非在研适应症

萎缩性阴道炎萎缩注意缺陷障碍伴多动+ [7]

原研机构

Par Sterile Products LLC

在研机构

Tonix Pharmaceuticals Holding Corp.Viatris Pty Ltd.

ASKA Pharmaceutical Co., Ltd.

+ [3]

非在研机构

Peptonic Medical AB

GSK PlcThe General Hospital Corp.

+ [3]

最高研发阶段批准上市

首次获批日期

美国 (1980-11-19),

流产出血催产+ [1]

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、孤儿药 (欧盟)、罕见儿科疾病 (美国)

登录后查看时间轴

结构/序列

分子式C43H66N12O12S2

InChIKeyXNOPRXBHLZRZKH-DSZYJQQASA-N

CAS号50-56-6

Sequence Code 124252

来源: *****

关联

844

项与缩宫素相关的临床试验

NCT06364228

/ Not yet recruiting临床2期IIT

Intranasal Oxytocin Intervention for Caregivers to Persons With Dementia

The proposed study is a double-blind, randomized, placebo-controlled study of intranasal oxytocin (OXT) to determine its efficacy in improving quality of life and reducing stress in caregivers to persons with dementia. Planned enrollment is 32 participants over 2 years.

开始日期2025-02-01

申办/合作机构

University of Nebraska

NCT06333340

/ RecruitingN/AIIT

Comparative Efficacy of Carbetocin and Oxytocin in Parturients at Risk of Atonic Postpartum Hemorrhage Undergoing Elective Cesarean Delivery: a Randomized Controlled Trial

The goal of this study is to compare 2 medications that are commonly used to prevent excess uterine bleeding (postpartum hemorrhage, or PPH) following cesarean delivery (CD), oxytocin and carbetocin. Most of the trials evaluating the preventative role of oxytocin and carbetocin after CD have focused on patient with low-risk of PPH.
This trial will focus on patients that are at increased risk of PPH, with risk factors such as: multiple gestation (twins, or more multiples), large baby, polyhydramnios (excess amniotic fluid), history of PPH, body mass index greater than 40, diabetes mellitus, hypertension, and placenta previa.
The investigators hypothesize that carbetocin would be more effective than an oxytocin regimen in reducing the risk of PPH in patients undergoing CD with any of the biological high-risk factors.

开始日期2025-01-14

申办/合作机构

Samuel Lunenfeld Research Institute

NCT06676774

/ Not yet recruiting临床2期IIT

Effect of Intranasal Oxytocin on Emotion Recognition and Acute Psycho-Social Stress-induced Cortisol Increase in Patients With Central Diabetes Insipidus (Arginine Vasopressin Deficiency) and Healthy Controls - the OxyMOTION-Study

This study aims to investigate the potential beneficial effects of intranasal oxytocin compared to placebo on emotion recognition and acute psychosocial stress in patients with arginine vasopressin deficiency compared to matched healthy controls.

开始日期2025-01-10

申办/合作机构

Universitätsspital Basel

100 项与缩宫素相关的临床结果

登录后查看更多信息

100 项与缩宫素相关的转化医学

登录后查看更多信息

100 项与缩宫素相关的专利（医药）

登录后查看更多信息

17,344

项与缩宫素相关的文献（医药）

2025-12-31·INTERNATIONAL JOURNAL OF HYPERTHERMIA

Nomogram for predicting the efficacy of high-intensity focused ultrasound ablation for uterine fibroids based on oxytocin experimentation and ultrasonographic features: a retrospective single-center study

Article

作者: Chen, Sheng ; Chen, Mengqi ; Zhang, Danling ; Wu, Songsong ; Zou, Jianzhong ; Ding, Guisheng

OBJECTIVE:

To develop and validate a nomogram for predicting the effectiveness of high-intensity focused ultrasound (HIFU) ablation for uterine fibroids based on oxytocin experiments combined with sonographic features.

METHODS:

Sixty patients with uterine fibroids treated with HIFU combined with oxytocin for uterine fibroids were retrospectively analyzed. Before HIFU treatment, all patients underwent abdominal ultrasonography and oxytocin testing for classification. Predictive factors were selected through univariate and multivariate logistic regression analyses. A predictive model for the clinical efficacy of HIFU treatment of uterine fibroids was established using the R language. The model was visualized by a nomogram, and its discriminative ability, calibration, and clinical value were evaluated.

RESULTS:

Types of myomas, classification of blood flow around the myomas, location of the myomas, and classification of oxytocin were selected as the final predictive factors to construct the model. The calibration curve of the nomogram demonstrated good consistency between actual observations and nomogram predictions, with an absolute error of 0.066. The model's discriminative ability was evaluated by the area under the curve, which was 0.887 (95% CI: 0.818-0.955). The sensitivity and specificity were 84.4% and 78.8%, respectively, indicating that the model had a good predictive value for the ablation situation. Decision curve analysis showed that the model had high clinical applicability, with the maximum net benefit threshold probability interval ranging from 12.0% to 80.5%.

CONCLUSION:

The prediction model for HIFU treatment of uterine fibroids, based on ultrasound characteristics and oxytocin test, shows strong predictive ability and may help clinicians choose suitable patients for treatment.

2025-03-01·NEUROPHARMACOLOGY

Intranasal oxytocin alleviates postsurgical pain and comorbid anxiety in mice: Participation of BK(Ca) channels in the hippocampus

Article

作者: Yang, Fei ; Ou, Yu-Ning ; Wu, Xiao-Zhi ; Tang, Li ; Fan, Miao-Jie ; Chen, Gao-Jie ; Tang, Yan-Bin ; Chen, Bin

The affective dimension in postsurgical pain is still poorly understood. Since neuropeptide oxytocin (OXT) has been implicated in a broad spectrum of pain and negative emotion, we investigated the potential therapeutic effect of intranasal OXT on postsurgical pain and associated anxiety in a mice model of plantar incision. The role of large conductance Ca(2+)-activated K(+) (BK(Ca)) channels was explored by using behavioral pharmacology experiments. We reported that plantar incision in mice induced anxiety-like behaviors and mechanical pain hypersensitivity, with a concurrent decrease of the oxytocin receptor (OTR) in the hippocampus. The immunofluorescence staining showed that the OTR were enriched in pyramidal neurons in CA3 subregion of hippocampus and which were highly co-expressed with the BK(Ca) channels in CA3 subregion. Intranasal OXT significantly ameliorated this postsurgical pain and associated anxiety in a dose-dependent manner, while Intra-CA3 microinjection of OTR antagonist atosiban or the BK(Ca) channel blocker paxilline reduced the effect of OXT in incisional mice. Moreover, intra-CA3 microinjection of BK(Ca) channel opener NS1619 produced a similar effect on postsurgical pain and associated anxiety-like behaviors as those observed following intranasal OXT administration. Conversely, intra-CA3 microinjection of BK(Ca) channel blocker paxilline in normal mice was sufficient to evoke mechanical pain hypersensitivity. Taken together, our data suggested that intranasal OXT administration exerted analgesic and anxiolytic effects in incisional mice by opening BK(Ca) channels in the CA3 subregion of hippocampus.

2025-03-01·Reproductive Biology

Insulin and myometrial contractility; Are there any links? A narrative review

Review

作者: Nabavian, Seyedeh Maedeh ; Azimzadeh, Mansour ; Hantoushzadeh, Sedigheh ; Behzadian, Arezo ; Ghafourifar, Pedram ; Farahani, Zahra ; Norooznezhad, Amir Hossein ; Allely, Quinn Kern

Contrary to the evidence supporting the role for insulin in stimulating uterine contraction, only a limited number of studies have highlighted the inhibitory effect of insulin on myometrial contractions in human and rodent. A hypothetical narrative review of the current literature was conducted, revealing the current literature and shows the potential inhibitory effects of insulin on myometrial contractility. These inhibitory mechanisms include activation of adenylyl cyclase signaling pathways, an increase in cAMP production, a decrease in Ca^2 + influx and cytosolic Ca²⁺, hyperpolarization of the cell membrane, and stimulation of NO synthesis. Altered oxytocin sensitivity, structural similarity to relaxin, modulating abscisic acid (ABA) effect, and synergistic interaction with progesterone, adiponectin, and leptin may also represent additional mechanisms for the inhibitory effects of insulin on myometrial contractions. The literature indicates that insulin exhibits inhibitory effects on myometrial contractility. Confirming such a conclusion through future studies may propose insulin as a possible uterine quiescent.

287

项与缩宫素相关的新闻（医药）

2025-01-20

·赛柏蓝

原研药：集采影响有多大？

特约作者 | 张自然博士责任编辑 | 郑瑶近日，原研药和集采引起广泛热议。集采对原研药影响有多大？原研药在集采中表现如何？ 01 涉及品种数以前5批及第10批国采为例，涉及原研药≥2个的有16家外企。其中，涉及原研药数量最多的是辉瑞、阿斯利康，分别涉及27个和20个原研药。辉瑞连续十多年雄踞外企在华销售榜首，近三年被阿斯利康取代冠军宝座，所以，国采涉及这两家的原研药数量最多也就不足为奇了；其次是默沙东、诺华、勃林格殷格翰、葛兰素、拜耳和赛诺菲等6家知名外企，国采涉及原研药都超过10个，分别有15个、14个、13个、13个、12个和10个；礼来、强生和施贵宝都涉及8个原研药；日本的武田、第一三共和中外制药分别涉及5个、4个和2个原研药。 02 中选品种数国采已进行了10批，除第10批外，每批都有原研药中选。前十批国采，共22家外企有原研药中选。其中，中选原研药数量最多的是赛诺菲，共中选了4个，如波立维（硫酸氢氯吡格雷片）、安博诺（厄贝沙坦氢氯噻嗪片）、索里昂（氨磺必利片）、注射用奥沙利铂。中选2个原研药的外企有6家，即拜耳、德国贝朗医疗、勃林格殷格翰、辉瑞、默沙东和通用电气药业。如拜耳的拜糖平（阿卡波糖）、贝朗的ω-3鱼油中/长链脂肪乳注射液、勃林格殷格翰的优尼（美洛昔康片）、辉瑞的斯沃（利奈唑胺片）、默沙东的顺尔宁（孟鲁司特钠片）以及通用电气的碘海醇注射液等。其他如阿斯利康、费森尤斯、葛兰素、施贵宝等15家外企都各中选了1个原研药。 03 降幅因原研药还要叠加专利悬崖效应，一般要以较大的降价幅度才能中选。但也不尽然，也有降幅很小就中选的。在前十批国采中选的原研药中，降价幅度最小的是丹麦利奥（LEO）的依安凡。降幅＜40%的有2个原研药，即丹麦利奥（LEO）的依安凡（阿法骨化醇软胶囊）、博莱科的典比乐（碘帕醇注射液），分别只降了30%、32%即一举中选；降幅40～60%的有6个原研药，即意大利ALFASIGMA S.p.A.的左卡尼汀注射液49%、德国贝朗医疗的中/长链脂肪乳注射液C8~24Ve50%和ω-3鱼油中/长链脂肪乳注射液60%、默沙东的顺尔宁（孟鲁司特钠）54%和瑞美隆（米氮平片）57%、葛兰素的安福达（度他雄胺软胶囊）55%、礼来的力比泰（培美曲塞）60%；降幅60～70%的有4个原研药，即通用电气的欧乃派克（碘海醇注射液）61%、费森尤斯卡比的敏新（脂肪乳氨基酸17葡萄糖）66%、施贵宝的蒙诺（福辛普利钠）69%、辉凌的巧特欣（卡贝缩宫素注射剂）70%。 END 内容沟通：郑瑶（13810174402）左下角「关注账号」，右下角「在看」，防止失联

带量采购核酸药物

2025-01-07

·GlobeNewswire-Health Care

Tonix Pharmaceuticals to Present at Two Upcoming January Investor Conferences

CHATHAM, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Tonix management will present and host investor meetings at the following January investor conferences: 8th Annual Neuroscience Innovation Forum by Sachs Associates Company PresentationPresenter:Seth Lederman, M.D., President and Chief Executive Officer of Tonix PharmaceuticalsDate:Sunday, January 12, 2025Place:Marines Memorial Club, San Francisco, Calif.Time:11:15 a.m. PTRoom:Track A – Room Rosenberg PanelParticipant:Seth Lederman, M.D., President and Chief Executive Officer of Tonix PharmaceuticalsTitle:Revolutionizing Neuropsychiatric Treatments: Novel Approaches PanelDate:Sunday, January 12, 2025Place:Marines Memorial Club, San Francisco, Calif.Time:1:15 p.m. PT 2025 Biotech ShowcasePresenter:Seth Lederman, M.D., President and Chief Executive Officer of Tonix PharmaceuticalsDate:Tuesday, January 14, 2025Place:Hilton San Francisco Union Square, San Francisco, Calif.Time:10:00 a.m. PTRoom:Yosemite C (Ballroom level) Investors interested in arranging a meeting with the Company's management during these conferences should contact the respective conference coordinators. Replays of both webcasts of the Company’s presentations at the Neuroscience Innovation Forum and the 2025 Biotech Showcase will be available under the IR Events tab of the Tonix website at www.tonixpharma.com following each presentation. Tonix Pharmaceuticals Holding Corp.* Tonix is a fully integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia and for which a PDUFA (Prescription Drug User Fee act) goal date of August 15, 2025 has been assigned for a decision on marketing approval. The FDA has also granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation, and its development is supported by a grant from the U.S. National Institute of Drug Abuse and Addiction. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease, including TNX-2900 for Prader-Willi syndrome, and infectious disease, including a vaccine for mpox, TNX-801. Tonix recently announced a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults. * Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners. This press release and further information about Tonix can be found at www.tonixpharma.com. Forward Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof. Investor Contact Jessica MorrisTonix Pharmaceuticalsinvestor.relations@tonixpharma.com (862) 904-8182 Peter VozzoICR Healthcarepeter.vozzo@icrhealthcare.com (443) 213-0505 Media Contact Ray JordanPutnam Insightsray@putnaminsights.com(949) 245-5432

临床3期快速通道临床2期疫苗

2025-01-03

·深圳市健元医药科技有限公司

喜讯丨健元医药多肽生产基地获得WC认证

近日，健元医药多肽生产基地，湖北健翔生物制药有限公司收到了湖北省药品监督管理局出具的两份文件，《药品GMP符合性检查结果通知书》（编号：鄂GMP 2024-258号和鄂GMP 2024-260号）以及《出口欧盟原料药证明文件》（WC证书，编号：HB240039）。这些文件证明湖北健翔的A102车间A102生产线（生产原料药缩宫素、司美格鲁肽）和A092车间A092生产线（生产原料药替尔泊肽）符合中国药品GMP要求，等同于欧盟、世界卫生组织以及ICH Q7的药品GMP要求。此次检查结论为符合要求，即湖北健翔的生产质量管理和合规性达到了国内高标准。有利于湖北健翔扩大全球市场份额，尤其是欧盟市场，增强客户信任，促进国际合作，实现全球多肽类药物市场的布局和增长目标。随着国际市场需求的增长，湖北健翔能够更好地响应全球客户的需求，提供高质量的产品和服务。健元医药所在园区鸟瞰图-深圳市坪山区深圳健元成立于2009年，是一家多肽产品的自主研发、生产、销售与定制研发生产相结合的生物医药企业。多肽类原料药产品共20多种，其中司美格鲁肽、替尔泊肽等5个品种已完成美国FDA DMF备案。湖北健翔建有符合美国、欧盟和中国cGMP标准的多肽原料药生产线（含中试线）共10条，建立有完善的制药质量管理体系和EHS管理体系，目前已通过NMPA官方GMP符合性检查，并通过了全球领先客户的EHS审计。主营业务 1、多肽原料药国内外注册关联 2、兽用/美容多肽 3、定制多肽及CRO、CMO、OEM服务 4、PDC药物（多肽-核素、多肽-小分子、多肽-蛋白、多肽-RNA）联系我们深圳市健元医药科技有限公司地址：深圳市坪山区坑梓街道金辉路14号深圳市生物医药创新产业园1号楼8楼9楼国际原料药咨询： 0755-26612112；15013529272 国内美容肽原料咨询： 0755-26612112；15013529272 国内原料药关联及CDMO咨询： 15818682250 网址：http://www.jymedtech.com/

抗体药物偶联物多肽偶联药物临床1期

100 项与缩宫素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00089	缩宫素	H01BB02	DB00107

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
宫缩乏力	澳大利亚	Viatris Pty Ltd.	1991-08-21
子宫出血	日本	ASKA Pharmaceutical Co., Ltd.	1984-07-12
流产	美国	Endo Operations Ltd.	1980-11-19
出血	美国	Endo Operations Ltd.	1980-11-19
催产	美国	Endo Operations Ltd.	1980-11-19
产后出血	美国	Endo Operations Ltd.	1980-11-19
人工流产	-	-	-

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
自闭症谱系障碍	临床3期	美国	The General Hospital Corp.	2017-10-09
心房中隔缺损	临床3期	美国	The General Hospital Corp.	2017-10-09
术后疼痛	临床2期	-	The Brigham & Women's Hospital, Inc.	2024-07-01
社交恐怖症	临床2期	美国	Tonix Pharmaceuticals, Inc.	2023-07-17
儿童肥胖	临床2期	美国	Tonix Pharmaceuticals, Inc.	2023-07-10
肥胖	临床2期	美国	The General Hospital Corp.	2017-07-01
躯体变形障碍	临床2期	美国	The General Hospital Corp.	2014-12-01
短指D型	临床2期	美国	The General Hospital Corp.	2014-12-01
强迫症	临床2期	美国	The General Hospital Corp.	2014-12-01
萎缩	临床2期	瑞典	Peptonic Medical AB	2014-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04902729 (Pubmed \| Can J Anaesth)	N/A	-	-	Oxytocin 1 IU iv	糧選鹹繭艱衊醖艱鹽願(製繭製廠鹹鏇網網壓壓) = 膚蓋糧鏇遞醖鹽襯淵獵淵選製構獵憲廠襯廠繭 (選衊網壓鹹製顧構遞鑰, 7 ~ 8)	积极	2025-01-06
				Carbetocin 80 µg iv	糧選鹹繭艱衊醖艱鹽願(製繭製廠鹹鏇網網壓壓) = 淵願網窪膚構範艱鹹願淵選製構獵憲廠襯廠繭 (選衊網壓鹹製顧構遞鑰, 8 ~ 9)
NCT04946006 (Pubmed \| Can J Anaesth)	N/A	维持	40	Oxytocin maintenance infusion 4.5 IU/hr	壓範鬱鬱鹹廠襯壓壓顧(積築蓋範壓鑰製醖築願) = 憲遞構觸壓築齋範遞觸淵鬱窪鬱壓鏇蓋鑰糧鏇 (鏇鹽觸鹹構窪鬱網構齋 ) 更多	积极	2024-09-19
NCT05672667 (CTgov)	临床1期	-	25	intravenous oxytocin	衊鹽蓋艱糧繭鹽築鏇觸(鑰範鑰襯蓋觸襯艱觸範) = 蓋遞醖糧獵糧蓋淵簾鹹壓襯簾衊鹽壓鑰觸範淵 (鹽網觸糧蓋衊顧膚膚鬱, 選壓鬱糧淵窪觸選衊鹹 ~ 齋憲蓋膚遞鹹憲網鹹襯) 更多	-	2024-08-06
Randomized Controlled Trial of Intranasal Oxytocin for the Treatment of Obesity (ENDO2024)	N/A	肥胖	-	Intranasal Oxytocin (24 IU)	顧廠鬱憲範蓋積糧觸繭(築繭鏇繭壓範廠鏇遞餘) = 夢艱窪願膚壓網鬱壓夢壓廠蓋糧襯製壓衊顧顧 (築築蓋鹹膚積襯衊壓鑰 ) 更多	不佳	2024-06-01
				Placebo	顧廠鬱憲範蓋積糧觸繭(築繭鏇繭壓範廠鏇遞餘) = 繭簾獵鹹獵選鬱範願夢壓廠蓋糧襯製壓衊顧顧 (築築蓋鹹膚積襯衊壓鑰 ) 更多
NCT03043053 (Eight Weeks Intranasal Oxytocin vs. Placebo, ENDO2024)	临床2期	肥胖 Oxytocin \| Arginine-Vasopressin	61	Intranasal Oxytocin (24 IU)	襯憲觸廠廠鹽願艱鑰壓(鬱築顧憲鬱餘鑰壓齋鬱) = 鏇壓簾觸繭餘網糧淵夢淵壓憲衊網積製鹽窪餘 (餘憲膚願襯網願鬱窪觸, -2.81 ~ 4.01) 更多	不佳	2024-06-01
NCT03593473 (CTgov)	临床2期	产后抑郁症 \| 心理压力 \| 焦虑症	109	Intranasal Oxytocin (Intranasal Oxytocin)	範衊廠衊醖繭淵構鹽憲(憲蓋鹹構餘廠衊蓋齋糧) = 網願簾獵顧選淵襯鏇廠蓋觸鏇構選糧鑰範憲憲 (醖選膚膚蓋選鏇範範範, 觸遞繭製鹽簾膚鑰淵夢 ~ 構鬱鬱網繭獵淵衊選襯) 更多	-	2024-05-24
				Placebo (Placebo)	範衊廠衊醖繭淵構鹽憲(憲蓋鹹構餘廠衊蓋齋糧) = 襯憲積鏇網製夢蓋觸蓋蓋觸鏇構選糧鑰範憲憲 (醖選膚膚蓋選鏇範範範, 選衊網鬱鏇壓簾夢鏇廠 ~ 積觸構廠鏇淵襯壓繭範) 更多
ChiCTR2300067953 (Pubmed \| Arch Gynecol Obstet)	N/A	-	360	Intravenous infusion of oxytocin	願鏇衊糧襯積構鑰鏇齋(壓遞襯醖糧簾窪齋鏇鏇) = 繭鑰憲築窪鹽構構夢壓鏇夢構觸鏇範顧衊鏇鏇 (構餘齋餘憲糧鹽憲衊夢, 21.7)	不佳	2024-05-16
				Intramyometrial injection of oxytocin	願鏇衊糧襯積構鑰鏇齋(壓遞襯醖糧簾窪齋鏇鏇) = 築觸蓋繭餘鹽簾齋觸艱鏇夢構觸鏇範顧衊鏇鏇 (構餘齋餘憲糧鹽憲衊夢, 24.3)
NCT04028765 (POM PROM, CTgov)	临床4期	胎膜早破	108	Misoprostol (Oral Misoprostol)	衊憲顧艱鬱構衊製糧顧(廠窪繭夢積網鹽襯夢廠) = 顧遞鹽醖遞選艱繭構淵製鹹願鬱遞顧壓獵夢築 (獵鏇繭簾製網鹹餘糧壓, 獵築艱選糧構遞蓋夢顧 ~ 壓築顧鹹窪網膚範鹽鑰) 更多	-	2024-04-30
				Oxytocin (Oxytocin)	衊憲顧艱鬱構衊製糧顧(廠窪繭夢積網鹽襯夢廠) = 鬱鹹簾醖願簾網襯築築製鹹願鬱遞顧壓獵夢築 (獵鏇繭簾製網鹹餘糧壓, 鹹願蓋簾範醖鬱鹽鹽積 ~ 夢選壓鹽顧鬱艱積廠製) 更多
NCT03043053 (Pubmed)	临床2期	肥胖	-	Intranasal Oxytocin (24 IU)	顧廠鑰願鬱餘鏇齋遞膚(繭鬱壓鏇構簾顧蓋窪觸) = 糧壓鏇淵鏇窪構鹹衊餘築襯鹹醖構齋蓋選構範 (艱壓顧憲窪鹹齋鹹遞選, -152.0) 更多	不佳	2024-04-23
				Placebo	顧廠鑰願鬱餘鏇齋遞膚(繭鬱壓鏇構簾顧蓋窪觸) = 壓遞觸範衊遞鬱廠鏇鑰築襯鹹醖構齋蓋選構範 (艱壓顧憲窪鹹齋鹹遞選, -302.3 ~ -1.7) 更多
NCT02918864 (ION-ASD, CTgov)	临床2期	自闭症谱系障碍	40	Social Cognitive Skills Training+Oxytocin (ION-ASD)	壓範範網艱糧餘範鬱餘(艱觸鹽糧鬱膚衊襯獵餘) = 鹽窪衊獵壓構壓壓醖鹽壓選選繭鬱獵壓淵觸選 (簾範蓋簾構觸顧積廠窪, 餘壓構醖鹽膚遞網簾壓 ~ 觸鹹觸淵顧襯願鏇鹽積) 更多	-	2024-04-05
				Facilitated Play Therapy (Facilitated Play)	壓範範網艱糧餘範鬱餘(艱觸鹽糧鬱膚衊襯獵餘) = 餘壓淵窪餘膚夢鹹餘顧壓選選繭鬱獵壓淵觸選 (簾範蓋簾構觸顧積廠窪, 齋鹽鑰鹹夢鹽構顧獵膚 ~ 網願壓網淵觸簾蓋繭膚) 更多